The state of UK drug discovery: the pharmaphorum podcast

The UK environment for drug discovery, the impact of artificial intelligence (AI) on medicines research and the role of complex cell models were all on the agenda for episode 12 of the pharmaphorum podcast.

On it I spoke with Chris Molloy, who’s CEO at the UK’s Medicines Discovery Catapult, about the Catapult’s State of the Discovery Nation publication, a joint report with the UK’s biotech trade body the BioIndustry Association.